Polaris AI Pharma Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Polaris AI Pharma's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals Industry Growth | 11.3% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Why EstechPharma Co., Ltd. (KOSDAQ:041910) Is A Top Dividend Stock
Apr 01If You Had Bought EstechPharma's (KOSDAQ:041910) Shares Five Years Ago You Would Be Down 60%
Mar 06Declining Stock and Solid Fundamentals: Is The Market Wrong About EstechPharma Co., Ltd. (KOSDAQ:041910)?
Feb 07We're Not So Sure You Should Rely on EstechPharma's (KOSDAQ:041910) Statutory Earnings
Jan 17Is EstechPharma Co., Ltd.'s (KOSDAQ:041910) 0.8% Dividend Worth Your Time?
Dec 22A Look At EstechPharma's (KOSDAQ:041910) Share Price Returns
Dec 01Revenue & Expenses BreakdownBeta
How Polaris AI Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 22 | 63,935 | 989 | 6,226 | 2,964 |
30 Jun 22 | 63,929 | 1,958 | 6,251 | 3,008 |
31 Mar 22 | 65,510 | 5,428 | 6,615 | 3,167 |
31 Dec 21 | 60,401 | 6,875 | 5,884 | 3,194 |
30 Sep 21 | 58,826 | 13,746 | 5,671 | 2,933 |
30 Jun 21 | 61,602 | 13,826 | 5,475 | 3,009 |
31 Mar 21 | 61,174 | 16,221 | 5,337 | 3,242 |
31 Dec 20 | 61,324 | 15,733 | 5,269 | 3,301 |
30 Sep 20 | 61,369 | 11,269 | 5,604 | 3,447 |
30 Jun 20 | 57,387 | 11,723 | 5,488 | 3,373 |
31 Mar 20 | 52,245 | 16,749 | 5,358 | 3,164 |
31 Dec 19 | 46,490 | 15,228 | 5,292 | 3,281 |
30 Sep 19 | 43,683 | 14,336 | 4,210 | 3,240 |
30 Jun 19 | 40,322 | 11,516 | 4,267 | 3,251 |
31 Mar 19 | 39,999 | 6,596 | 4,249 | 3,456 |
31 Dec 18 | 40,336 | 6,590 | 4,322 | 3,567 |
30 Sep 18 | 38,601 | 6,703 | 4,522 | 3,735 |
30 Jun 18 | 37,803 | 7,395 | 4,423 | 3,899 |
31 Mar 18 | 36,687 | 3,432 | 4,491 | 3,579 |
31 Dec 17 | 38,214 | 2,726 | 4,470 | 3,287 |
30 Sep 17 | 39,444 | 5,008 | 4,478 | 3,534 |
30 Jun 17 | 39,908 | 4,315 | 4,447 | 3,309 |
31 Mar 17 | 43,550 | 3,556 | 4,507 | 3,426 |
31 Dec 16 | 43,397 | 4,148 | 4,733 | 3,396 |
30 Sep 16 | 44,851 | -136 | 5,056 | 2,918 |
30 Jun 16 | 46,509 | -382 | 5,078 | 2,781 |
31 Mar 16 | 44,615 | -154 | 4,890 | 2,437 |
31 Dec 15 | 45,066 | -870 | 4,810 | 2,464 |
30 Sep 15 | 43,815 | 2,743 | 3,862 | 2,364 |
30 Jun 15 | 43,526 | 4,573 | 4,173 | 2,253 |
31 Mar 15 | 42,768 | 2,246 | 5,212 | 2,153 |
31 Dec 14 | 44,215 | 3,029 | 6,431 | 1,965 |
30 Sep 14 | 41,991 | -788 | 5,541 | 2,721 |
30 Jun 14 | 43,034 | -1,764 | 6,992 | 1,573 |
31 Mar 14 | 45,564 | 2,468 | 5,605 | 2,039 |
31 Dec 13 | 42,247 | 3,703 | 4,361 | 1,587 |
30 Sep 13 | 52,009 | 8,074 | 6,251 | 0 |
30 Jun 13 | 54,565 | 9,830 | 6,334 | 0 |
Quality Earnings: Insufficient data to determine if A041910 has high quality earnings.
Growing Profit Margin: Insufficient data to determine if A041910's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A041910's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare A041910's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if A041910's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: A041910 has a negative Return on Equity (0%), as it is currently unprofitable.